Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks

Item

http://www.wikidata.org/entity/Q28269931

Q28269931

about

Efficacy, safety, and patient acceptability of elvitegravir/cobicistat/emtricitabine/tenofovir in the treatment of HIV/AIDS Dolutegravir - a review of the pharmacology, efficacy, and safety in the treatment of HIV Resistance against Integrase Strand Transfer Inhibitors and Relevance to HIV Persistence Efavirenz-Based Regimens in Antiretroviral-Naive HIV-Infected Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials Clinical use of HIV integrase inhibitors: a systematic review and meta-analysis An Indirect Comparison of Efficacy and Safety of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil Fumarate and Abacavir/Lamivudine + Dolutegravir in Initial Therapy Therapy-Emergent Drug Resistance to Integrase Strand Transfer Inhibitors in HIV-1 Patients: A Subgroup Meta-Analysis of Clinical Trials What's new for antiretroviral treatment in women with HIV Switching from twice-daily raltegravir plus tenofovir disoproxil fumarate/emtricitabine to once-daily elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate in virologically suppressed, HIV-1-infected subjects: 48 weeks data.HIV integrase inhibitors: a new era in the treatment of HIV.Clinical Improvement by Switching to an Integrase Strand Transfer Inhibitor in Hemophiliac Patients with HIV: The Japan Cohort Study of HIV Patients Infected through Blood Products Critical appraisal of elvitegravir in the treatment of HIV-1/AIDS.Early virologic response to abacavir/lamivudine and tenofovir/emtricitabine during ACTG A5202.French 2013 guidelines for antiretroviral therapy of HIV-1 infection in adults.Novel approaches to HIV therapy.Safety and tolerability of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Disoproxil fumarate in a real life setting: Data from surveillance cohort long-term toxicity antiretrovirals/antivirals (SCOLTA) project.Inflammation, Immune Activation, and Antiretroviral Therapy in HIV A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe.Cobicistat: a Novel Pharmacoenhancer for Co-Formulation with HIV Protease and Integrase Inhibitors Single-Tablet Regimens in HIV Therapy Resistance analyses of integrase strand transfer inhibitors within phase 3 clinical trials of treatment-naive patients.Contribution of the organic anion transporter OAT2 to the renal active tubular secretion of creatinine and mechanism for serum creatinine elevations caused by cobicistat Altered viral fitness and drug susceptibility in HIV-1 carrying mutations that confer resistance to nonnucleoside reverse transcriptase and integrase strand transfer inhibitors.48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysis.Rapid screening of HIV reverse transcriptase and integrase inhibitors.Tenofovir: What We Have Learnt After 7.5 Million Person-Years of Use.HIV-associated lipodystrophy: impact of antiretroviral therapy.Dolutegravir, the Second-Generation of Integrase Strand Transfer Inhibitors (INSTIs) for the Treatment of HIV.Cost-effectiveness of rapid hepatitis C virus (HCV) testing and simultaneous rapid HCV and HIV testing in substance abuse treatment programs Once-Daily, Single-Tablet Regimens For the Treatment of HIV-1 Infection What if HIV were unable to develop resistance against a new therapeutic agent?Simian-tropic HIV as a model to study drug resistance against integrase inhibitors.The lifetime medical cost savings from preventing HIV in the United States.Antiretroviral therapy: when to start Genome-wide association study of virologic response with efavirenz-containing or abacavir-containing regimens in AIDS clinical trials group protocols.Systematic Literature Review and Meta-Analysis of Renal Function in Human Immunodeficiency Virus (HIV)-Infected Patients Treated with Atazanavir (ATV)-Based Regimens.Impact of antiretroviral therapy on lipid metabolism of human immunodeficiency virus-infected patients: Old and new drugs.Cost-Effectiveness of Single- Versus Generic Multiple-Tablet Regimens for Treatment of HIV-1 Infection in the United States.Differential Reduction in Monocyte Activation and Vascular Inflammation With Integrase Inhibitor-Based Initial Antiretroviral Therapy Among HIV-Infected Individuals.Safety, Pharmacokinetics and Efficacy of Dolutegravir in Treatment-experienced HIV-1 Infected Adolescents: Forty-eight-week Results from IMPAACT P1093

P2860

Q26783253-7DBB95E1-8289-44EA-9A60-4333EB6F5A7A Q26799712-0CDCE698-5DCC-4B1C-9B0B-2258D5658FCA Q26801286-C8F1BA8E-96AB-41C7-9717-7FFD6C6E2109 Q28081266-6D0EE1EC-4540-46EA-ADFE-58CFB3C99E50 Q28484930-94AEA0BE-0515-4699-855C-BB0E915C1C55 Q28552210-7C216DE8-BBE3-493B-8610-CC87F8070241 Q28553571-2DAA297C-8E90-453D-80AC-E9CE474E20F4 Q30391322-04050688-21CE-467E-BE8A-DA1099CF4A17 Q30795793-276FF5C4-6FB2-400F-888A-44B58815A541 Q30956943-A3366F29-8D64-4E22-B0AD-2BD44EED2AD2 Q33668385-D681C398-B36A-40A0-B2D2-5A630B984C46 Q33680234-C1FF1EA2-9FAE-478F-B52E-41CA0E1D1213 Q33767281-F0391048-828A-4847-B9BB-B8D34A238399 Q33775397-5709B629-CBAC-42B7-9192-DE2C6475A5D0 Q33777819-D70C128D-F807-4EB9-8386-97AFC786E20E Q33817410-CA5E988E-5A18-4522-9A2C-EEB7DC59990A Q33912595-87D9FBA1-4C2A-4465-BC82-6D54C977045F Q33922073-50D88120-4A91-452D-A3C9-DFA6BB147B3B Q33939069-62CDA1BE-846F-49A6-8871-2E85948C60A7 Q33939110-A4A58BE9-E659-4C8B-A7C7-7079E3CE5EDA Q33963458-AA891BD6-2DED-4696-B550-53E760BCE3AE Q33997420-ABEF0AED-6423-461F-B0F7-DEB315BEC717 Q34059119-159DF207-0E89-4B0A-BBC3-8735252CED3F Q34134900-B802A78B-8913-4F67-9CE6-8C98FE2048D1 Q34193340-26C6619A-0345-4F95-95F4-35D6F1BFD2D3 Q34478840-A94C3315-D013-433C-A5E7-3C074FE60997 Q34655845-15C94395-6F81-427C-B48F-703C2C5C0C7B Q34726183-BE42E437-755C-4512-BF20-2D5DFE9EE900 Q34735072-22CEA785-B91E-4017-8E71-600F9C72751A Q34976284-F443BB19-4FE9-4931-A0D9-4A6050A304D5 Q35051393-8B995441-D268-4AEA-94EA-F4ED79275150 Q35169003-B1E64943-E35C-4D42-94DC-69BE6F79D917 Q35177401-8B57CA7C-BDA6-4438-BAFA-A7F12966D5FE Q35204279-A62CA17E-0F59-40F9-94C8-13EB5CD11CDD Q35288691-2DBD48DD-3AD8-4EE8-9686-610B8B6E3397 Q35566732-2622B40A-D8D3-4C4A-A84C-1365DAC47068 Q35567828-C95A976F-F24E-4BC6-9DFA-0DE158181B4D Q35903617-E4B0FAF1-806C-4582-AB76-3B070228C341 Q35965242-7AC13A56-B6D6-4A5A-BDE2-3EBCADB7CCCA Q36157266-57E5C326-57AB-4CA4-B675-5F55C38EBF1E

P2860

Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir versus co-formulated efavirenz, emtricitabine, and tenofovir for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3 trial, analysis of results after 48 weeks

Item

http://www.wikidata.org/entity/Q28269931

description

2012 nî lūn-bûn

@nan

2012 թուականի Յունիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հունիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu